Statement: There were no patients with paranasal sinus reactions in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 21/107 (19.63%)   Febrile neutropenia * 10/107 (9.35%)   Neutropenia * 1/107 (0.93%)   Left ventricular dysfunction * 0/107 (0.00%)   Angina pectoris * 0/107 (0.00%)   Cardiac failure congestive * 0/107 (0.00%)   Diarrhoea * 2/107 (1.87%)   Abdominal strangulated hernia * 0/107 (0.00%)   Duodenal ulcer haemorrhage * 0/107 (0.00%)   Pyrexia * 1/107 (0.93%) Adverse Events 2:   Total: 22/107 (20.56%)   Febrile neutropenia * 8/107 (7.48%)   Neutropenia * 6/107 (5.61%)   Left ventricular dysfunction * 3/107 (2.80%)   Angina pectoris * 1/107 (0.93%)   Cardiac failure congestive * 0/107 (0.00%)   Diarrhoea * 0/107 (0.00%)   Abdominal strangulated hernia * 1/107 (0.93%)   Duodenal ulcer haemorrhage * 0/107 (0.00%)   Pyrexia * 1/107 (0.93%)